Iovance Biotherapeutics (IOVA) SEC Filings: History & Chart

Iovance Biotherapeutics, Inc.(IOVA)

Biotechnology · San Carlos, CA

$13.10-1.05 (-7.46%)

Delayed quote: Oct 6, 2026, 3:15 PM EDT

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

San Carlos, CA

975 employees

www.iovance.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Frederick G. Vogt

View full financials

Form	Filing Date	Accepted	Document
8-K	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 2, 2026	Oct 2, 2026	View filing
3	Oct 2, 2026	Oct 2, 2026	View filing
8-K	Sep 29, 2026	Sep 29, 2026	View filing
4	Sep 10, 2026	Sep 10, 2026	View filing
4	Sep 10, 2026	Sep 10, 2026	View filing
4	Sep 10, 2026	Sep 10, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
SC 13G/A	Jul 28, 2026	Jul 28, 2026	View filing
8-K	Jul 2, 2026	Jul 2, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
S-8	Jun 18, 2026	Jun 18, 2026	View filing
S-8	Jun 18, 2026	Jun 18, 2026	View filing
S-3ASR	Jun 18, 2026	Jun 18, 2026	View filing
8-K	Jun 10, 2026	Jun 10, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing
4	Jun 9, 2026	Jun 9, 2026	View filing

SEC Filings

Recent Filings